Assessing the Value of Integrated Evidence Approaches in Drug Development
Use of value drivers and eNPV-based value models when planning for IEPs can provide objective guidance for project teams. The value can be estimated through formal economic analysis that considers planned timelines, R&D costs, estimates of the likelihood of regulatory approval, patient access and clinical adoption if development is successful.
Authors
- Gorana Capkun (ORCID: https://orcid.org/0000-0001-9566-4456)
- Zachary Smith (ORCID: https://orcid.org/0000-0002-6764-1350)
- Joseph A. DiMasi (ORCID: https://orcid.org/0000-0002-3432-6928)
- Melvin Olson (ORCID: https://orcid.org/0000-0002-2870-4443)
- Kenneth Getz (ORCID: https://orcid.org/0000-0003-0568-2541)
Institutions
- Tufts University (US)
- Merck KGaA, Darmstadt (Germany) (DE)
- Actelion (Switzerland) (CH)
Publication Details
- Journal
- Therapeutic Innovation & Regulatory Science
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1007/s43441-025-00778-y
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novartis